Novigenix Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 19

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $1.96M

  • Investors
  • 4

Novigenix General Information

Description

Developer of a precision medicine platform designed for the detection of disease, therapy optimization, and disease recurrence monitoring. The company's platform is optimized for mapping the immune system's response to the onset and progression of the disease by integrating patient multi-omics data, advanced machine learning, and artificial intelligence (AI) approaches, providing medical professionals with actionable insights and precision tools for optimizing patients' therapeutic journeys.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Route de la Corniche 3
  • Phenyl Building, Biopôle IV
  • 1066 Epalinges
  • Switzerland
+41 021
Primary Industry
Decision/Risk Analysis
Other Industries
Outcome Management (Healthcare)
Corporate Office
  • Route de la Corniche 3
  • Phenyl Building, Biopôle IV
  • 1066 Epalinges
  • Switzerland
+41 021

Novigenix Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novigenix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 09-Apr-2025 $1.96M Completed Generating Revenue
4. Accelerator/Incubator 18-Feb-2025 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2024 Completed Generating Revenue
2. Later Stage VC (Series B) 15-Nov-2022 $20M $20M Completed Generating Revenue
1. Grant 21-Jan-2021 $1.22M Completed Startup
To view Novigenix’s complete valuation and funding history, request access »

Novigenix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a precision medicine platform designed for the detection of disease, therapy optimization, and disease recu
Decision/Risk Analysis
Epalinges, Switzerland
19 As of 2025

Cambridge, United Kingdom
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Novigenix Competitors (26)

One of Novigenix’s 26 competitors is Congenica, a Formerly VC-backed company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Congenica Formerly VC-backed Cambridge, United Kingdom
Superfluid DX Venture Capital-Backed South San Francisco, CA
Freenome Formerly VC-backed Brisbane, CA
Boreal Genomics Formerly VC-backed Vancouver, Canada
Tempus AI Formerly VC-backed Chicago, IL
You’re viewing 5 of 26 competitors. Get the full list »

Novigenix Patents

Novigenix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4782555-A1 Methods for analysing and predicting response to a immune checkpoint blockade therapy Pending 27-Jan-2025
WO-2026159317-A1 Methods for analysing and predicting response to a immune checkpoint blockade therapy Pending 27-Jan-2025
EP-4584399-A1 Methods to predict response to icbt of a patient having cancer Pending 07-Sep-2022
US-20260071280-A1 Methods to predict response to icbt of a patient having cancer Pending 07-Sep-2022
WO-2024052233-A9 Methods to predict response to icbt of a patient having cancer Inactive 07-Sep-2022 C12Q1/6886
To view Novigenix’s complete patent history, request access »

Novigenix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novigenix Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Innovative Medicines Initiative Government
Microsoft for Startups Accelerator/Incubator
Matwin Accelerator/Incubator
Eurostars Other
To view Novigenix’s complete investors history, request access »

Novigenix Acquisitions (1)

Novigenix’s most recent deal was a Merger/Acquisition with Diagnoplex. The deal was made on 12-Feb-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Diagnoplex 12-Feb-2015 Merger/Acquisition Laboratory Services (Healthcare)
To view Novigenix’s complete acquisitions history, request access »

Novigenix FAQs

  • When was Novigenix founded?

    Novigenix was founded in 2014.

  • Where is Novigenix headquartered?

    Novigenix is headquartered in Epalinges, Switzerland.

  • What is the size of Novigenix?

    Novigenix has 19 total employees.

  • What industry is Novigenix in?

    Novigenix’s primary industry is Decision/Risk Analysis.

  • Is Novigenix a private or public company?

    Novigenix is a Private company.

  • What is Novigenix’s current revenue?

    The current revenue for Novigenix is .

  • How much funding has Novigenix raised over time?

    Novigenix has raised $20M.

  • Who are Novigenix’s investors?

    Innovative Medicines Initiative, Microsoft for Startups, Matwin, and Eurostars have invested in Novigenix.

  • Who are Novigenix’s competitors?

    Congenica, Superfluid DX, Freenome, Boreal Genomics, and Tempus AI are some of the 26 competitors of Novigenix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process